Your browser doesn't support javascript.
loading
Continuous irrigation with thrombolytics for intraventricular hemorrhage: case-control study.
Carrera, Diego A; Mabray, Marc C; Torbey, Michel T; Andrada, Jason E; Nelson, Danika E; Sarangarm, Preeyaporn; Spader, Heather; Cole, Chad D; Carlson, Andrew P.
Afiliação
  • Carrera DA; Department of Neurology, University of New Mexico, Albuquerque, NM, USA.
  • Mabray MC; Department of Radiology, University of New Mexico, Albuquerque, NM, USA.
  • Torbey MT; Department of Neurology, University of New Mexico, Albuquerque, NM, USA.
  • Andrada JE; Department of Neurology, University of New Mexico, Albuquerque, NM, USA.
  • Nelson DE; School of Medicine, University of New Mexico, Albuquerque, NM, USA.
  • Sarangarm P; Department of Pharmacy, University of New Mexico Hospital, Albuquerque, NM, USA.
  • Spader H; Department of Neurosurgery, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA.
  • Cole CD; Department of Neurosurgery, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA.
  • Carlson AP; Department of Neurology, University of New Mexico, Albuquerque, NM, USA. AndrewCarlson@salud.unm.edu.
Neurosurg Rev ; 47(1): 40, 2024 Jan 10.
Article em En | MEDLINE | ID: mdl-38200247
ABSTRACT
Intraventricular hemorrhage (IVH) is a complication of a spontaneous intracerebral hemorrhage. Standard treatment is with external ventricular drain (EVD). Intraventricular thrombolysis may improve mortality but does not improve functional outcomes. We present our initial experience with a novel irrigating EVD (IRRAflow) that automates continuous irrigation with thrombolysis.Single-center case-control study including patients with IVH treated with EVD compared to IRRAflow. We compared standard demographics, treatment, and outcome parameters between groups. We developed a brain phantom injected with a human clot and assessed clot clearance using EVD/IRRAflow approaches with CT imaging.Twenty-one patients were treated with standard EVD and 9 patients with IRRAflow. Demographics were similar between groups. Thirty-three percent of patients with EVD also had at least one dose of t-PA and 89% of patients with IRRAflow received irrigation with t-PA (p = 0.01). Mean drain days were 8.8 for EVD versus 4.1 for IRRAflow (p = 0.02). Days-to-clearance of ventricular outflow was 5.8 for EVD versus 2.5 for IRRAflow (p = 0.02). Overall clearance was not different. Thirty-seven percent of EVD patients achieved good outcome (mRS ≥ 3) at 90 days versus 86% of IRRAflow patients (p = 0.03). Assessing only t-PA, reduction in mean days-to-clearance (p = 0.0004) and ICU days (p = 0.04) was observed. In the benchtop model, the clot treated with IRRAflow and t-PA showed a significant reduction of volume compared to control.Irrigation with IRRAflow and t-PA is feasible and safe for patients with IVH. Improving clot clearance with IRRAflow may result in improved clinical outcomes and should be incorporated into randomized trials.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Cerebral / Fibrinolíticos Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Cerebral / Fibrinolíticos Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article